pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
raps·1d ago·1 min read
save

This Week at FDA: Overton nomination pulled, FDA promotes international reliance, and more

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical device regulation, and what we’re reading from around the web. This week, the Trump administration withdrew its FDA commissioner nominee at the eleventh hour, FDA announced a program to help sponsors market products in other countries, and announced several firsts in product approvals.

Nov 20, 2026·read at raps ↗

20 Nov 2026 Docket commenters call for flexibility in rare disease trial design and evidence, but question FDA’s RCT focus Comments to the US Food and Drug Administration (FDA) public docket on statistical considerations for study designs in rare disease clinical investigations supported the need for flexibility in trial design and evidence for rare diseases, but a few asked the agency to reconsider its focus on randomized controlled trials. Regulatory News

source

Reporting by raps.

read at raps ↗
71 words · retrieved 8m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1d agoFinal ICH Q1 stability testing guideline expected to be released soonraps
  • 1d agoDocket commenters call for flexibility in rare disease trial design and evidence, but question FDA’s RCT focusraps
  • 1d agoFDA officials detail inspection expectations for combination productsraps
  • 2d agoRecon: FDA approves drugs for four rare diseases; Pfizer signs $2.6B licensing deal in China for in vivo CAR-Traps
  • 2d agoEuro Roundup: UK MHRA launches service to support early consideration of good practicesraps